I agree this looks like new information. That's five hospitals...

I agree this looks like new information. That's five hospitals lined up in Australia and only a few months away.

This company continues to quietly deliver upon its undertakings in what I consider to be a thoroughly professional way. In my judgement it is getting virtually no recognition of this by the market - probably on an absolute valuation basis and unquestionably on a relative basis - but if it is successful that means it has all the more upside.

Just an observation about my words "if it is successful" and the article's "a promising therapy". This completely understates and fails to recognise the confidence the Company has in the device. The probability of success, perhaps not 100%, is extremely high, because of the history of the technology and the results of trials which for corporate reasons were not concluded.

The technology will almost certainly achieve positive outcomes for many patients suffering from pancreatic cancer and when this occurs the product will sell itself because of the terrible nature of the disease. It will be able to treat many more indications with its new technology platform called OncoCal.

The stock is held back by a diminishing overhang and modest news flow, both which will disappear from the radar in H2 2014 as the initial results of the trial start coming through. There is real substance to this company and that will become apparent in due course.